Lenalidomide (CC-5013)

For research use only.

Catalog No.S1029

95 publications

Lenalidomide (CC-5013) Chemical Structure

CAS No. 191732-72-6

Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 70 In stock
USD 147 In stock
USD 407 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Lenalidomide (CC-5013) has been cited by 95 publications

Purity & Quality Control

Choose Selective E3 ligase Ligand Inhibitors

Biological Activity

Description Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.
Targets
CRBN [3]
()
VEGF [1]
()
TNF-α [1]
(PBMCs)
13 nM
In vitro

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC NGrDRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJwMUWwN|gh|ryP MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
L-363 NI\CdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\wTWM2OD1{LkmyNlEzKM7:TR?= NGnn[oM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
JAR MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XKS2lEPTB;Mj65O|AxOSEQvF2= Ml;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
EoL-1-cell NHnyZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnD[2NxUUN3ME20MlExPTF3IN88US=> NFnuWHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
BT-549 NHLsR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LCNmlEPTB;Nj6yNVg1QSEQvF2= M3\4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
SK-NEP-1 NXvWTWdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnsRYlKSzVyPUeuPFk2OTJizszN MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
BV-173 NVvlPXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRThwNke1PFUh|ryP M{Gzc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
HMV-II NYjJVmhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7KTWM2OD1zMD6wNVczKM7:TR?= NWfxbHh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HCC1806 NIm0TVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr0RXRbUUN3ME2xNU41PDZ5IN88US=> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
KASUMI-1 M{DKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjL[3h6UUN3ME2xNU42PzFizszN MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
SK-MEL-28 M2jkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFzLkm3OlQh|ryP MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
RPMI-8226 NH3qUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjKPI42UUN3ME2xNk43OjRzIN88US=> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
T47D M1W4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF|LkKwPVkh|ryP MnrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HOP-62 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrJNGtbUUN3ME2xN{41QCEQvF2= M1vkXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
A2058 NVvZNG1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjjTWM2OD1zMz64NVk6KM7:TR?= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
SW620 M1jOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTD[IlKSzVyPUG0MlI1PzNizszN MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
LCLC-103H NHX4XldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfRU|RqUUN3ME2xOE41QDl{IN88US=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HAL-01 NYPHd|M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3UPJlVUUN3ME2xOE42Pzl4IN88US=> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
PANC-08-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzGfWNKSzVyPUG0MlkyODhizszN NWT1SmFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
COLO-684 MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrWTWM2OD1zNT6zPVc6KM7:TR?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
DEL NVK5bmhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7vTWM2OD1zNT60PVkh|ryP MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
K5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrwOINKSzVyPUG2MlE1QDZizszN MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
SK-MEL-24 NYjSdFdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDvUG0{UUN3ME2xOk41PjV{IN88US=> M1Xv[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ACN M4\LUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfONIs2UUN3ME2xOk42Ojl5IN88US=> NHewUJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
H9 M1PrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPHW4lKSzVyPUG2MlYzPiEQvF2= NWfubI81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EM-2 MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vqUmlEPTB;MUeuNVQ{KM7:TR?= NHHTVHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HSC-4 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\1NpZKSzVyPUG3MlY3ODFizszN M2jt[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
IGROV-1 NWLiZYp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\5TWM2OD1zNz63PFMh|ryP NGXNPFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
TE-1 NILQVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\wTWM2OD1zNz65PVY5KM7:TR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
LN-405 NF;RWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfRXolKSzVyPUG5MlkxPzZizszN NUHkbYNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
MSTO-211H NGXlXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PrVGlEPTB;MkCuN|U4OyEQvF2= MmHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
MOLT-4 MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJyLkW3OVkh|ryP NHTYVGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
RS4-11 NWqwfnE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W4fGlEPTB;MkKuNVU3OyEQvF2= M1\HZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ES3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rLTGlEPTB;MkKuOlk3OyEQvF2= M2C5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
SBC-1 NUKyd496T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ|Lki2PVYh|ryP M2rRS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
CTV-1 M3e0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL2TWM2OD1{NT6wNVQ6KM7:TR?= NIrSOHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HuP-T3 M1LOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP5TFNKSzVyPUK1MlQxODlizszN M2K4e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
HCC2218 NGXO[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ3LkW0NFch|ryP Mn7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HDLM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ6LkKwNlYh|ryP M2TxNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ABC-1 NGLIfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofjTWM2OD1{OT62PVc1KM7:TR?= MnntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
MV-4-11 NGi3fnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;NV2pKSzVyPUK5Mlc{OTdizszN MlPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
WM-115 M2jCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fld2lEPTB;M{CuN|A6QSEQvF2= NW\aW5JwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
SW1990 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFftfppKSzVyPUOwMlM{KM7:TR?= NH7yeVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HCC70 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnaNHRKSzVyPUOwMlc{PDZizszN NXvZe2h3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
KYSE-520 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljFTWM2OD1|MD64PFM6KM7:TR?= M4r3V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
JEG-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn61TWM2OD1|MT6xOlE1KM7:TR?= NW[3OGZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
C8166 NXO5XWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrRTWM2OD1|MT6yNlc1KM7:TR?= NFnP[|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SK-OV-3 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNzLk[3OVUh|ryP MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NCI-H526 NVGzPVdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3HPY9WUUN3ME2zNk43QDNizszN MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NKM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzIdWtKSzVyPUOyMlk2PjhizszN M2\lSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ECC10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknyTWM2OD1|ND63OFQ{KM7:TR?= NWHydldMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
A2780 M1LqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTN3LkO2NFEh|ryP M2DlcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KY821 NIT5N|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;k[WlEPTB;M{WuO|Y5OSEQvF2= NFHGZXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
MKN1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrLd3NwUUN3ME2zOk4zOTN5IN88US=> MmPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
EKVX NF73eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzGRVlWUUN3ME2zO{41OjF{IN88US=> M3XkNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
EW-16 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljUTWM2OD1|OD6zPFg2KM7:TR?= NE\ve209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
CTB-1 M1;vSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXBTGZKSzVyPUO5Mlc4QDlizszN NUnnSFN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
COR-L105 NXLQ[3dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrEWFZKSzVyPUSwMlQ4PDZizszN M3HaSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-SNU-5 M2XUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTofWdWUUN3ME20NU4zODZ7IN88US=> NWnG[2Y3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
Mewo NXT6UJhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7sTWM2OD12MT65PFcyKM7:TR?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
BCPAP NXfxcW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTR|Lke5NVch|ryP Ml33QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
KARPAS-45 NF7FbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTR2LkK3O|Yh|ryP M3P0ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H1693 NWjse4UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLrdoQ6UUN3ME20Ok43QTh4IN88US=> MlHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
H-EMC-SS NIXNTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLsNWFKSzVyPUS4MlMzOjRizszN MlXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
697 NEXxcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO1TWM2OD13MD6zOVQ2KM7:TR?= NYTVZohSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
KP-N-YS NGrYTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXVOINNUUN3ME21Nk4{OTR{IN88US=> MljrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NCI-H1304 M4\jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr6TWM2OD13Mj63NFI1KM7:TR?= NVK5RWxJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NOS-1 NW\SOphjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m0NmlEPTB;NUKuPFU2QSEQvF2= MonrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NCI-H2342 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT1TWM2OD13Mz6wOVA5KM7:TR?= Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
KYSE-270 NETyPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTV|Lk[zOlQh|ryP NVjC[5VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
LU-135 NGrMNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL2O2tKSzVyPUW1MlE5PTNizszN NGewXXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
OE33 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDRTWM2OD13NT64NVgh|ryP MmnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ML-2 Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13rbGlEPTB;NUWuPVQ5QSEQvF2= NVfvXXgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
KMOE-2 M4XpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnJTWM2OD13Nj6yPFk{KM7:TR?= NX7t[Y9lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
Daoy NXnLVYJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljLTWM2OD13Nj6zNlA1KM7:TR?= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
KNS-62 NV3BUJNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u2OGlEPTB;NUeuNFE1OiEQvF2= MnewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NBsusSR Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofaTWM2OD13Nz61O|A2KM7:TR?= MkXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
UACC-257 M4XYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH1TWM2OD13OD62NlY1KM7:TR?= MoDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
LU-139 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTV6LkiyOkDPxE1? MnrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
CAL-85-1 NYHXV5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTV6Lki2OFMh|ryP NXWzNlZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H720 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqzV4lKSzVyPUW4Mlg6PDJizszN NXLwdll3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
MLMA NVG3VZF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTV7LkC5NUDPxE1? NHLNeIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
A3-KAW NHzzbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LW[WlEPTB;NUmuNlgxQSEQvF2= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
Ramos-2G6-4C10 NYn2fGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrJWI5KSzVyPUW5MlYzQDdizszN MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
A388 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTZyLkS0PUDPxE1? NWC2XYo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
LAMA-84 NXX4U212T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK1TWM2OD14MD65PVA2KM7:TR?= M4D5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
GCT MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:xOGlEPTB;NkGuNFc5PiEQvF2= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
K-562 M{j4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZzLkWzN|Mh|ryP M13Ib|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H1666 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzQPIVKSzVyPU[xMlg4PSEQvF2= M{XWZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H1993 M17qR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjJTWM2OD14Mz60NFQ{KM7:TR?= Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NCI-H358 M1P5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTZ3LkCxNlEh|ryP NYrVNZdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NB6 NITYUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTZ3Lkm4PEDPxE1? MkXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HCE-T MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;t[GhGUUN3ME22O{4xPzl6IN88US=> M4f0R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
DOK Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fpO2lEPTB;NkeuOFk1QCEQvF2= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HT-1376 NIHJS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHITWM2OD14OT64N|E1KM7:TR?= MoTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NEC8 NWLSWlZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTdyLkGyOFMh|ryP MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
G-402 M33tW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\VTWM2OD15MD65N|k2KM7:TR?= M2\wRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
GR-ST M{\abGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTdzLkG3NkDPxE1? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
QIMR-WIL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfTUlZKSzVyPUexMlQ1OzRizszN M4PINVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
CHP-212 NET3fYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKxTWM2OD15MT65OlUh|ryP M2LYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KU812 M4HxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjHTWM2OD15Mj65O|AzKM7:TR?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
Becker NVLCSZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTd|LkG0PFkh|ryP M2LmNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ChaGo-K-1 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTGTnpKSzVyPUe0Mlc1QDZizszN M1PtTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
A498 NVH3Z3pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmxTWM2OD15ND65N|A5KM7:TR?= NYfJXXhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H69 M4jsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS4O|JKSzVyPUe1Mlc3PjNizszN MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NCI-H209 NUXaXWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPZTWM2OD15OD62NVQ4KM7:TR?= Mne4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
CAL-33 M3W4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ry[mlEPTB;N{iuPVk{QSEQvF2= NYPQPZp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
COLO-680N NITPbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fT[WlEPTB;N{muNVAxPyEQvF2= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
D-283MED MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rtSmlEPTB;N{muPFEzKM7:TR?= Mmn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ATN-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PpZWlEPTB;OEGuNVE5PyEQvF2= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NCI-N87 MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT1NHh6UUN3ME24NU44Ojl4IN88US=> NGLyT2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
MHH-NB-11 M134emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkTWM2OD16MT64PFQ6KM7:TR?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTh{LkSxN|Qh|ryP NEntc2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NB69 NUTQNndFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljITWM2OD16Mz6wNFM{KM7:TR?= MlnBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
MPP-89 M16yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jIcGlEPTB;OEOuNlU4PSEQvF2= NXO2XHBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
COLO-829 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nsNWlEPTB;OEWuOFkyOiEQvF2= NGPk[Xg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ONS-76 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvaTWM2OD16NT63PVA5KM7:TR?= NXLDVHM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EW-3 NGr3blFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\kTmlEPTB;OE[uNlA{OiEQvF2= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
EW-11 MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HmTmlEPTB;OE[uOFM{PiEQvF2= MnzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
SW900 NWHBfGZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTh5LkKwOVMh|ryP M4HsVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
MOLT-13 NGm4fnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\RZ2lEPTB;OEeuNlI1OyEQvF2= Mnv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HuP-T4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6wdZM6UUN3ME25NU4xPDB3IN88US=> NXrZdlBwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HCC1419 M{TkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljNTWM2OD17MT62N|c1KM7:TR?= NFu2SXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
CAL-72 M160UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPV[|VLUUN3ME25Nk4xOjF7IN88US=> M13SfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Mo-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXmcZlpUUN3ME25Nk44Pjl5IN88US=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
OC-314 NYmxbI0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TMOmlEPTB;OUKuPFgzOSEQvF2= MnLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
BHT-101 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfWTWM2OD17Mz6xJO69VQ>? MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
EW-18 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L2Z2lEPTB;OUOuPFQ3OiEQvF2= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
TE-12 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK3TWM2OD17ND6zNFU2KM7:TR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
MDA-MB-361 NEnDXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTqSG1CUUN3ME25Ok4xPTF4IN88US=> NFfaeFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
DF15 MlTxSpVv[3Srb36gZZN{[Xl? NF76TJY1KGi{cx?= MnfETY5lfWO2aX;uJI9nKEOUTESvR3JDViC3YnnxeYl1cW5ibHnnZZNmNW2nZHnheIVlKGGrb3zvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy|IHX4dJJme3OrbnegdGxQSy2nUFyteIFo\2WmIHHpc4xweyCjZoTldkA1KGi{czDifUBtfW2rbnXzZ4Vv[2ViYnHz[YQh[mW2YT3nZYxi[3Sxc3nkZZNmKGWweont[UBnemGpbXXueIF1cW:wIHPvcZBt\W2nboTheIlwdiCjc4PhfUwhTUN3MDC9JFAvODV|IN88UU4> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3OEWwO{c,Ojh|NUi1NFc9N2F-
DF15 NEK1fphHfW6ldHnvckBie3OjeR?= NUG2b2FKPCCqcoO= M3G4bmlv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCra3Hyc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDlfJBz\XO|aX7nJIVRVC22YXfn[YQhcWujcn;zJIFnfGW{IESgbJJ{KGK7IHz1cYlvd22ndILpZ{BidmGueYPpd{whTUN3MDC9JFAvODZ5IN88UU4> M{T5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
DF15 MX7GeY5kfGmxbjDhd5NigQ>? MkTXOEBpenN? NHzIcYlKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW|c3nu[{BmWExvdHHn[4VlKGGrb3zvd{Bi\nSncjC0JIhzeyCkeTDseY1qdm:vZYTybYMh[W6jbInzbZMtKEWFNUCgQUAxNjB6NzFOwG0v NF6xWIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
T-cells MVfGeY5kfGmxbjDhd5NigQ>? NFnGZnkzKHSxIEOg[IF6ew>? MY\Jcohq[mm2aX;uJI9nKEmOLUKgdJJw\HWldHnvckBqdiCqdX3hckBVKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEKgeI8hOyCmYYnzJIJ6KEWOSWPBMEBGSzVyIE2gNE4yPSEQvF2u M2r6WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MU[4NFE6Lz5{M{G2PFAyQTxxYU6=
NAMALWA NV\FcIVGSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NH:0dYE4OiCqcoO= M4i1R2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlHNRWxYSSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwM{[g{txONg>? NVvIVZZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlgxOTlpPkKzNVY5ODF7PD;hQi=>
CD34+ progenitor cells MnH0SpVv[3Srb36gZZN{[Xl? MYWxOEBl[Xm| MYnE[YNz\WG|ZTDpckBmenm2aILvbYQh\GmoZnXy[Y51cWG2aX;uJI9nKEOGM{SrJJBzd2enbnn0c5Ih[2WubIOg[pJwdSCveXXsc4R6e3CuYYP0bYMhe3mwZILvcYUh\GWuKEXxLUBx[XSrZX70JIF{e2W|c3XkJIF{KEOGM{[g[ZhxemW|c3nvckBi\nSncjCxOEBl[Xm| MkP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3N{[5NlQoRjF5NUe2PVI1RC:jPh?=
CD34+ progenitor cells NVrFW3BoTnWwY4Tpc44h[XO|YYm= MlXiNVQh\GG7cx?= M1r4SmRm[3KnYYPlJIlvKG27ZXzvbYQh\GmoZnXy[Y51cWG2aX;uJI9nKEOGM{SrJJBzd2enbnn0c5Ih[2WubIOg[pJwdSCveXXsc4R6e3CuYYP0bYMhe3mwZILvcYUh\GWuKEXxLUBx[XSrZX70JIF{e2W|c3XkJIF{KEOGM{Og[ZhxemW|c3nvckBi\nSncjCxOEBl[Xm| MoHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3N{[5NlQoRjF5NUe2PVI1RC:jPh?=
CD34+ progenitor cells NF\vOpNHfW6ldHnvckBie3OjeR?= MoP3NVQh\GG7cx?= NY\i[3N[TGWlcnXhd4UhcW5iZYL5eIhzd2mmIHTp[oZmemWwdHnheIlwdiCxZjDDSFM1MyCycn;n[Y5qfG:{IHPlcIx{KG[{b32gcZlmdG:meYPwcIF{fGmlIIP5coRzd22nIHTlcEg2eSlicHH0bYVvfCCjc4Pld5Nm\CCjczDncJlkd3Cqb4LpckBCKGW6cILld5Nqd25iYX\0[ZIhOTRiZHH5dy=> M1nhfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUe2PVI1Lz5zN{W3OlkzPDxxYU6=
CD34+ progenitor cells MmflS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXmxOEBl[Xm| MlvVTY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25ib3[gR2Q{PCticILv[4VvcXSxcjDj[YxteyCocn;tJI16\WyxZInzdIxie3SrYzDzfY5lem:vZTDk[YwpPXFrIIDheIlmdnRiYX\0[ZIhOTRiZHH5dy=> M4DiN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUe2PVI1Lz5zN{W3OlkzPDxxYU6=
CD34+ progenitor cells M3XNTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlG4NVQh\GG7cx?= NWTnPVh5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiQ1SzOEsheHKxZ3XubZRweiClZXzsd{Bnem:vIH7vck1l\WxqNYGpJI16\WyxZInzdIxie3SrYzDzfY5lem:vZTDwZZRq\W62IHHmeIVzKDF2IHThfZM> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5NkmyOEc,OTd3N{[5NlQ9N2F-
DF15 M4m2cWZ2dmO2aX;uJIF{e2G7 NYj1XZdjOC5zIITvJFExKHWP NYDoclI4PSCqcoO= NFXRUpJKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOgZZQhOC5zIITvJFExKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NXvjUVdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 NHXGZZZHfW6ldHnvckBie3OjeR?= NEXXd48xNjFidH:gNVAhfU1? MUW1JIhzew>? MY\JcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQh[WmxbH;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE:STUKgZ4VtdHNiYYSgNE4yKHSxIEGwJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> NUL6W2g2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
DF15 MmTjSpVv[3Srb36gZZN{[Xl? M{faRVAvOSC2bzCxNEB2VQ>? NVXPNpNWPSCqcoO= MljLTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGmtYYLvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy|IHH0JFAvOSC2bzCxNEB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ M1OxfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
OPM2 NYrmdmRpTnWwY4Tpc44h[XO|YYm= MnqzNE4yKHSxIEGwJJVO NEHMfIE2KGi{cx?= MUPJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE:STUKgZ4VtdHNiYYSgNE4yKHSxIEGwJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> NI\5O3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
EC9706 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mn7UNVUxKHWpL33M NVf5PJlbPDhiaILz Mn3oRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCHQ{m3NFYh[2WubIOgZZQhOTVyIIXnM41NKGGodHXyJFQ5KGi{czDifUBES0tvODDhd5NigQ>? NH7scIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe1O|A3Pid-Mki3OVcxPjZ:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-IKKβ / IKKβ ; 

PubMed: 22698399     


Western blot analysis of the indicated proteins following treatment of OCI-Ly10 cells with lenalidomide (10μM) for the indicated times. 

MDM2 / p-MDM2 / p-p53 / p53 ; 

PubMed: 22525275     


(a) Treatment with lenalidomide (Len) increases phosphorylation of ser46 and thr55 of p53. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were prepared and analyzed by Western blotting with antibodies to MDM2, phospho-ser46 of p53, phospho-thr55 of p53 and total p53. (b) Treatment with lenalidomide increases phosphorylation of MDM2 at ser166 and ser186. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were immunoprecipitated using anti-MDM2 antibody. The samples were separated by SDS PAGE and then Western blotted with either anti-MDM2 or antibodies specific to phospho-ser166, phospho-ser186, total phospho-serine or total phospho-threonine of MDM2 as indicated. 

22698399 22525275
Growth inhibition assay
Cell viability; 

PubMed: 22698399     


Viability (MTS assay) of ABC and GCB DLBCL cell lines treated with lenalidomide for 4 days. Error bars show the standard error of the mean (SEM) of triplicates.

22698399
In vivo The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

Protocol

Animal Research:

[5]

- Collapse
  • Animal Models: Adult male Sprague-Dawley rats bearing HUVECs cells
  • Dosages: 50 mg/kg and 250 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG 300+5%Tween80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.26
Formula

C13H13N3O3

CAS No. 191732-72-6
Storage powder
in solvent
Synonyms N/A
Smiles C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04669171 Not yet recruiting Biological: EO2463|Drug: lenalidomide|Biological: rituximab Follicular Lymphoma|Marginal Zone Lymphoma Enterome April 15 2021 Phase 1|Phase 2
NCT03660072 Not yet recruiting Other: Non-Interventional Multiple Myeloma Bristol-Myers Squibb January 31 2021 --
NCT04191616 Recruiting Drug: Carfilzomib|Drug: Dexamethasone|Drug: Pomalidomide Relapsed or Refractory Multiple Myeloma Amgen August 6 2020 Phase 2
NCT04467281 Recruiting Drug: 89Zr-DFO-daratumumab|Diagnostic Test: PET/CT Multiple Myeloma Memorial Sloan Kettering Cancer Center June 30 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the formulation for mouse injection(i.p.)?

  • Answer:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • Question 2:

    what is the procedure to resuspend this compound?

  • Answer:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

E3 ligase Ligand Inhibitors with Unique Features

Tags: buy Lenalidomide (CC-5013) | Lenalidomide (CC-5013) supplier | purchase Lenalidomide (CC-5013) | Lenalidomide (CC-5013) cost | Lenalidomide (CC-5013) manufacturer | order Lenalidomide (CC-5013) | Lenalidomide (CC-5013) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID